Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients

Psychiatry Research

Volumn 168, Issue 2, 2009, Pages 110-118

  Baeza, Immaculada ^a   Castro Fornieles, Josefina ^a,b   Deulofeu, Ramon ^c   de la Serna, Elena ^a   Goti, Javier ^a   Salvà, Joan ^d   Bernardo, Miquel ^b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Acute psychosis; Dopamine; Negative syndrome; pHVA; Positive syndrome; Schizophrenia

Indexed keywords

BIPERIDEN; DOPAMINE; FLUNITRAZEPAM; HOMOVANILLIC ACID; LORAZEPAM; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MENTAL PATIENT; NEGATIVE SYNDROME; NEUROPATHOLOGY; PATIENT MONITORING; POSITIVE SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; RATING SCALE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DOPAMINE; FEMALE; FOLLOW-UP STUDIES; HOMOVANILLIC ACID; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYNDROME; TREATMENT OUTCOME;

EID: 67349239376     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.04.011     Document Type: Article

References (60)

1. Abi-Darham A. Do we still believe in the DA hypothesis? New data bring evidence. International Journal of Neuropsychopharmacology 7 Suppl 1 (2004) S1-S5
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), APA, Washington, DC
3. Amin F., Davidson M., Kahn R.S., Schmeidler J., Stern R., Knott P.J., and Apter S. Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schizophrenia Bulletin 21 (1995) 53-66
4. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS) (1983), University of Iowa, Iowa City
5. Andreasen N.C. The Scale for the Assesment of Positive Symptoms (SAPS) (1984), University of Iowa, Iowa City
6. Andreasen N.C., and Olsen S. Negative vs. positive schizophrenia. Definition and validation. Archives of General Psychiatry 39 (1982) 789-794
7. Blanchard J.J., and Cohen A.S. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophrenia Bulletin 32 (2006) 238-245
8. Carpenter W.T., Heinrichs D.W., and Gibbon M. Deficit and non-deficit forms of schizophrenia: the concept. American Journal of Psychiatry 14 (1988) 578-583
9. Chang W.H., and Hwu H.G. Plasma HVA and subtyping of schizophrenia. In: Friedhoff A.J., and Amin F. (Eds). Plasma Homovanillic Acid in Schizophrenia. Implications for Presynaptic Dopamine Dysfunction (1997), American Psychiatric Press, Inc., Washington, DC 43-59
10. Chang W.H., Scheinin M., Burns R.S., and Linnoila M. Rapid and simple determination of homovanillic acid in plasma using high performance liquid chromatography with electrochemical detection. Acta Pharmacologica et Toxicologica 53 (1983) 275-279
11. Chang W.H., Chen T.Y., Lin S.K., Lung F.W., Lin W.L., Hu W.H., and Yeh E.K. Plasma cathecolamine metabolites in schizophrenia: evidence for the two subtype concept. Biological Psychiatry 27 (1990) 510-518
12. Cuesta M.J., Peralta V., Gil P., and Artamendi M. Psychopathological dimensions in first-episode psychoses. European Archives of Psychiatry and Clinical Neuroscience 253 (2003) 73-79
13. Davidson M., and Davis K.L. A comparison of plasma homovanillic acid concentration in schizophrenic patients and normal controls. Archives of General Psychiatry 45 (1988) 561-563
14. Davidson M., Giordiani A.B., Mohs R.C., Mykytyn W., Plaff S., Aryan Z.S., and Davis K.L. Control of exogenous factors affecting plasma homovanillic acid concentration. Psychiatry Research 20 (1987) 307-312
15. Davidson M., Kahn R.S., Knott P., Kamisky R., Cooper M., DuMont K., Apter S., and Davis K.L. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Archives of General Psychiatry 48 (1991) 910-913
16. Davidson M., Kahn R.S., Stern R.G., Hirshchowitz J., Apter S., Knott P., and Davis K.L. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Research 46 (1993) 151-163
17. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry 148 (1991) 1474-1486
18. Friedhoff A.J., and Amin F. Plasma HVA as a tool to investigate presynaptic brain dopaminergic activity. In: Friedhoff A.J., and Amin F. (Eds). Plasma Homovanillic Acid in Schizophrenia. Implications for Presynaptic Dopamine Dysfunction (1997), American Psychiatric Press, Inc., Washington, DC 1-16
19. Galinowski A., Poirier M.F., Aymard N., Leyris A., Beauverie P., Bourdel M.C., and Loo H. Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol. Acta Psychiatrica Scandinavica 97 (1998) 458-466
20. Gasquet I., Haro J.M., Novick D., Edquell E.T., Kennedy L., Lepine J.P., and SOHO study group. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European schizhoprenia outpatient health outcome (SOHO) study. International Clinical Psychopharmacology 20 (2005) 199-205
21. Green A.I., Alam M.Y., Boshes R.A., and Sobieraj J.T. Haloperidol response and plasma catecholamines and their metabolites. Schizophrenia Research 10 (1993) 33-37
22. Green A.L., Alam M.Y., Sobieraj J.T., and Boshes R.A. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Research 46 (1993) 139-149
23. Green A.I., Tsuang M.T., and Schildkraut J.J. Cathecholamines, their metabolites and response to typical and atypical neuroleptics: toward an understanding of the mechanisms of action of the neuropeptic drugs. In: Friedhoff A.J., and Amin F. (Eds). Plasma Homovanillic Acid in Schizophrenia. Implications for Presynaptic Dopamine Dysfunction (1997), American Psychiatric Press, Inc., Washington. DC 61-77
24. Grunder G., Vernaleken I., Müller M.J., Davids E., Heydari N., Buchholz H.-G., Bartenstein P., Munk O.L., Stoeter P., Wong D.F., Gjedde A., and Cumming P. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28 (2003) 787-794
25. Kakihara S., Yoshimura R., Shinkai K., Matsumoto C., Goto M., Kaji K., Yamada Y., Ueda N., Ohmori O., and Nakamura J. Prediction of response to risperidone treatment with respect plasma concentrations of risperidone, cathecolamine metabolites, and polymorphism of cytocrome P450 2D6. International Clinical Psychopharmacology 20 (2005) 71-78
26. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry 160 (2003) 13-23
27. Kapur S., Mizrahi R., and Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research 79 (2005) 59-68
28. Kim Y., Kim L., and Lee M. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophrenia Research 44 (2000) 165-175
29. Labarca R., Silva H., Jerez S., Ruiz A., Forray M.I., Gyslinf K., Andres M.E., Bustos G., Castillo Y., and Hono H. Differential effects of haloperidol on negative symptoms in drug-naive schizophrenic patients: effects on plasma homovanillic acid. Schizophrenia Research 9 (1993) 29-34
30. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., and Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biological Psychiatry 46 (1999) 56-72
31. Leysen J.E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J.C., and Janssen P.A. Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics 247 (1988) 661-670
32. Liddle P.F. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dycothomy. British Journal of Psychiatry 151 (1987) 145-151
33. Lindström L.H. Low HVA and anormal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers. Correlation to symptomatology and family history. Psychiatry Research 14 (1985) 265-273
34. Maas J.W., Contreras S.A., Seleshi E., and Bowden C.L. Dopamine metabolism and disposition in schizophrenic patients. Archives of General Psychiatry 45 (1988) 553-560
35. Marneros A., and Tsuang M.T. Dichotomies and other distinctions in schizophrenia. In: Marneros A., Andreasen N.C., and Tsuang M.T. (Eds). Negative versus Positive Schizophrenia (1991), Springer-Verlag, Berlin 1-7
36. Mazure C.M., Nelson J.C., Jatlow P.I., and Bowers Jr. M.B. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biological Psychiatry 30 (1991) 475-482
37. Meltzer H.Y. Pre-clinical pharmacology of atypical antipsycotic drugs: a selective review. British Journal of Psychiatry 168 Suppl. 29 (1996) 23-31
38. Moore H., West A.R., and Grace A.A. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biological Psychiatry 46 (1999) 40-55
39. Moresco R.M., Cavallaro R., Messa C., Bravi D., Gobbo C., Galli L., Lucignani G., Colombo C., Rizzo G., Velonà I., Smeraldi E., and Fazio F. Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. Journal of Psychopharmacology 18 (2004) 355-365
40. Nibuya M., Kanba S., Sekiya U., Suzuki E., Matsuo Y., Kinoshita N., Shintani F., Yagi G., Asai M., Davis B.M., Johns C.A., DeNigris Y., and Horvarth T.B. Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Biological Psychiatry 38 (1995) 50-56
41. Oades R.D., Klimke A., Henning U., and Rao M.L. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia. Human Psychopharmacology 17 (2002) 15-27
42. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry 52 (1995) 998-1007
43. Ottong S.E., and Garver D.L. A bimodal distribution of plasma HVA/MHPG in the psychoses. Psychiatry Research 69 (1997) 9-103
44. Overall J.E., and Gorham D.R. The brief psychiatric rating scale. Psychological Reports 10 (1962) 799-812
45. Peralta V., Cuesta M.J., and Deleon J. An empirical analysis of latent structures underlying schizophrenic symptoms: a four-syndrome model. Biological Psychiatry 36 (1994) 726-736
46. Peralta V., Cuesta M.J., Martinez-Larrea A., and Serrano J.F. Differentiating primary from secundary negative symptoms in schizophrenia: a study of neuroleptic-naïve patients before and after treatment. American Journal of Psychiatry 157 (2000) 1461-1466
47. Pickar D., Labarca R., and Linnoila M. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 225 (1984) 954-957
48. Pickar D., Labarca R., Doran A.R., Wolkowitz O.M., Roy A., Breier A., Linnoila M., and Paul S.M. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Archives of General Psychiatry 43 (1986) 669-676
49. Pickar D., Breier A., Hsiao J.K., Doran A.R., Wolkowitz O.M., Pato C.N., Konicki P.E., and Potter W.Z. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis: implications for regional brain dysfunction in schizophrenia. Archives of General Psychiatry 47 (1990) 641-648
50. Ribeyre J.M., Lesieur P., Varoquaux O., Dollfus S., Pays M., and Petit M. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biological Psychiatry 36 (1994) 230-236
51. Simpson G.M., and Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 212 Suppl. (1970) 11-25
52. Soares J.C., and Innis R.B. Neurochemical brain imaging investigations of schizophrenia. Biological Psychiatry 46 (1999) 600-615
53. Stern R.G., Kahn R.S., and Davidson M. Review of plasma HVA studies in schizophrenia. In: Friedhoff A.J., and Amin F. (Eds). Plasma homovanillic acid in schizophrenia. Implications for presynaptic dopamine dysfunction (1997), American Psychiatric Press, Inc., Washington, DC 27-42
54. Suhara T., Okubo Y., Yasuno F., Sudo Y., Inoue M., Ichimiya T., Nakashima Y., Nakayama K., Tanada S., Suzuki K., Halldin C., and Farde L. Decreased dopamine D2 receptor binding in the anterior cingular cortex in schizophrenia. Archives of General Psychiatry 59 (2002) 31-34
55. Talvik M., Nordström A.-L., Okubo Y., Olsson H., Borg J., Halldin C., and Farde L. Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Research. Neuroimaging 148 (2006) 165-173
56. Thibaut F., Ribeyre J.M., Dourmap N., Ménard J.F., Dollfus S., and Petit M. Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. Biological Psychiatry 43 (1998) 24-30
57. van Kammen D.P., van Kammen W.B., Mann L.S., Seppala T., and Linnoila M. Dopamine metabolism in the cerebrospinal fluid of drug-free schhizophrenic patients with and without cortical atrophy. Archives of General Psychiatry 43 (1986) 978-983
58. Wong D.F., Wagner Jr. H.N., Tune L.E., Dannals R.F., Pearlson G.D., Links J.M., Tamminga C.A., Broussolle E.P., Ravert H.T., Wilson A.A., Toung J.K., Malat J., Williams J.A., O'Tuama L.A., Snyder S.H., Kuhar M.J., and Gjedde A. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234 (1986) 1558-1563
59. Yoshimura R., Ueda N., Shinkai K., and Nakamura J. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. International Clinical Psychopharmacology 22 (2003) 76-80
60. Zhang Z.J., Peet M., Ramchand C.N., Shah S., and Reynolds G.P. Plasma homovanillic acid in untreated schizophrenia-relationship with symptomatology and sex. Journal of Psychiatric Research 35 (2001) 23-28